Squarepoint
GSK icon

Squarepoint’s GSK GSK Stock Holding History

Squarepoint’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.46M Sell
62,711
-14,105
-18% -$764K ﹤0.01% 1775
2025
Q4 		$3.77M Buy
76,816
+9,528
+14% +$444K ﹤0.01% 1637
2025
Q3 		$2.9M Buy
67,288
+39,387
+141% +$1.54M ﹤0.01% 1809
2025
Q2 		$1.07M Sell
27,901
-69,889
-71% -$2.67M ﹤0.01% 2605
2025
Q1 		$3.79M Buy
97,790
+68,142
+230% +$2.49M ﹤0.01% 1612
2024
Q4 		$1M Buy
+29,648
New +$1.07M ﹤0.01% 3064
2024
Q3 		– Sell
-65,311
Closed -$2.67M – 4330
2024
Q2 		$2.51M Buy
+65,311
New +$2.75M ﹤0.01% 1870
2024
Q1 		– Sell
-122,062
Closed -$4.52M – 4235
2023
Q4 		$4.52M Buy
+122,062
New +$4.38M 0.01% 1457
2023
Q3 		– Sell
-31,582
Closed -$1.13M – 3970
2023
Q2 		$1.13M Sell
31,582
-91,172
-74% -$3.27M ﹤0.01% 2075
2023
Q1 		$4.37M Buy
122,754
+52,044
+74% +$1.82M 0.02% 957
2022
Q4 		$2.48M Sell
70,710
-244,503
-78% -$8.14M 0.01% 1241
2022
Q3 		$9.28M Buy
315,213
+296,143
+1,553% +$11.2M 0.05% 461
2022
Q2 		$1.04M Sell
19,070
-26,225
-58% -$1.45M 0.01% 1578
2022
Q1 		$2.47M Buy
45,295
+3,764
+9% +$204K 0.01% 1032
2021
Q4 		$2.29M Buy
+41,531
New +$2.16M 0.01% 1176
2021
Q3 		– Sell
-21,854
Closed -$1.09M – 3112
2021
Q2 		$1.09M Sell
21,854
-19,065
-47% -$916K ﹤0.01% 1570
2021
Q1 		$1.83M Sell
40,919
-52,931
-56% -$2.4M 0.01% 1126
2020
Q4 		$4.32M Buy
93,850
+76,189
+431% +$3.5M 0.03% 552
2020
Q3 		$831K Buy
+17,661
New +$885K 0.01% 1089
2020
Q2 		– Sell
-27,024
Closed -$1.28M – 2335
2020
Q1 		$1.28M Sell
27,024
-46,668
-63% -$2.49M 0.03% 618
2019
Q4 		$4.33M Buy
73,692
+64,849
+733% +$3.61M 0.03% 553
2019
Q3 		$472K Sell
8,843
-29,697
-77% -$1.53M ﹤0.01% 1651
2019
Q2 		$1.93M Sell
38,540
-751
-2% -$37.7K 0.02% 870
2019
Q1 		$2.05M Buy
+39,291
New +$1.96M 0.02% 762

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Squarepoint's GSK Position: Q1 2026 in Review

Squarepoint reduced its GSK (GSK) stake by 18% in Q1 2026, selling an estimated $764K and leaving 62,711 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Squarepoint first reported a position in GSK in Q1 2019 and has held it in 24 quarters since. The position peaked at $9.28M in Q3 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Squarepoint held 62,711 shares of GSK worth $3.46M as of Q1 2026.
  • Squarepoint sold 14,105 GSK shares in Q1 2026, an estimated $764K.
  • GSK made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1775 holding.
  • Squarepoint first reported a position in GSK in Q1 2019 and has held it in 24 quarters since.
  • Squarepoint's GSK position peaked at $9.28M in Q3 2022.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.